The granting of emergency use authorization by the U.S. FDA to Roche AG for its four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and respiratory syncytial virus will allow the company to quickly bring the test to near-patient care environments ahead of the flu season, to address a real need in the marketplace, Ian Parfrement, head of the point of care customer area, at Roche Diagnostics, told BioWorld.
Schrodinger Inc. and Takeda Pharmaceutical Co. Ltd. have identified 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Emory University has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Exevir Bio BV has demonstrated that its antibodies are potent in neutralizing the SARS-CoV-2 variant JN.1, the parental strain of the currently most dominantly circulating variants worldwide.
The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and the Wuhan Institute of Virology at the Chinese Academy of Sciences have divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Leyden Laboratories BV has patented polypeptides acting as spike glycoprotein (S) (SARS-CoV-2; COVID-19 virus) ligands reported to be useful for the treatment of SARS-CoV-2 infections.
Osaka, Japan-based Shionogi & Co. Ltd. said May 13 that ensitrelvir fumaric acid (Xocova), its oral antiviral for COVID-19, showed no statistical difference against placebo in completely resolving 15 common COVID-19-related symptoms in a global phase III Scorpio-HR trial.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized 3C-like proteinase (3CLpro, Mpro) (coronavirus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome infections.
There is still a need for developing more potent and broadly neutralizing vaccines against SARS-CoV-2 with improved durability. At the recent ESCMID meeting, Astrazeneca plc presented a new mRNA vaccine against the SARS-CoV-2 virus that encodes for self-assembling virus-like particle (VLP) antigens.
Tocris Cookson Ltd., Helmholtz Zentrum fur Infektionsforschung GmbH and University of Lübeck have described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands covalently bonded to non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) targeting moiety through linker reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
